Standard brentuximab vedotin schedule vs early discontinuation on clinician’s decision in patients with CTCL: a multicenter, retrospective study from the FIL Cutaneous Lymphomas Task Force
Titel:
Standard brentuximab vedotin schedule vs early discontinuation on clinician’s decision in patients with CTCL: a multicenter, retrospective study from the FIL Cutaneous Lymphomas Task Force